Oral Treatment for Atopic Dermatitis (L20.9)
For moderate-to-severe atopic dermatitis requiring oral systemic therapy, start with JAK inhibitors (upadacitinib, abrocitinib, or baricitinib) or dupilumab as first-line agents, as these have the strongest evidence and safety profiles for long-term use. 1
First-Line Oral Systemic Agents
The 2024 AAD guidelines make strong recommendations for three oral JAK inhibitors based on high-quality evidence 1:
- Upadacitinib (15 mg or 30 mg daily)
- Abrocitinib (100 mg or 200 mg daily)
- Baricitinib (2 mg or 4 mg daily)
These agents are preferred over traditional immunosuppressants because they have FDA approval specifically for atopic dermatitis, require no routine laboratory monitoring before initiation, and demonstrate superior efficacy in clinical trials 1.
JAK Inhibitor Selection Considerations
All three JAK inhibitors show comparable efficacy, so selection should be based on:
- Patient age and comorbidities: Screen for cardiovascular risk factors, history of thrombosis, malignancy, and active infections
- Baseline laboratory values: Check CBC with differential, comprehensive metabolic panel, lipid panel, and tuberculosis screening 2
- Platelet count: Abrocitinib requires baseline platelets >150 × 10⁹/L and should be avoided if concerns for thrombocytopenia exist 2
- Renal/hepatic function: Dose adjustments may be needed for moderate-to-severe impairment
Monitoring Requirements for JAK Inhibitors
Unlike traditional immunosuppressants, JAK inhibitors require less intensive monitoring 2:
- Baseline: TB screening, pregnancy test (if applicable), HBV/HCV, CBC, CMP, lipid panel
- 4-12 weeks after initiation: CBC with differential, CMP
- Every 3-6 months: CBC with differential, CMP
- Annually: Lipid panel
Common pitfall: Do not stop abrocitinib unless platelets fall below 50 × 10⁹/L; temporary decreases between 50-150 × 10⁹/L may occur but typically resolve 2.
Second-Line Oral Agents (Conditional Recommendations)
If JAK inhibitors are contraindicated or unavailable, the AAD makes conditional recommendations for traditional immunosuppressants 1:
Cyclosporine
- Dosing: 3-5 mg/kg/day divided twice daily
- Duration: Limited to 1 year maximum due to nephrotoxicity and hypertension risks
- Best for: Rapid disease control needed; acts faster than other agents
- Major limitation: Not FDA-approved for AD (off-label use); requires monitoring of blood pressure, creatinine, and drug interactions 1
Methotrexate
- Dosing: Start 7.5-15 mg weekly, can increase to 25 mg weekly
- Requires: Folic acid supplementation (1 mg daily or 5 mg weekly)
- Monitoring: Baseline and periodic CBC, liver enzymes, creatinine
Mycophenolate Mofetil/Mycophenolic Acid
- Dosing: Mycophenolate mofetil 2-3 g/day divided twice daily (or equivalent mycophenolic acid 720-1080 mg/day)
- Note: 360 mg mycophenolic acid = 500 mg mycophenolate mofetil 1
Azathioprine
- Dosing: 1-3 mg/kg/day
- Requires: TPMT testing before initiation to assess metabolism
These traditional agents have conditional (weaker) recommendations because they lack FDA approval for AD, require more intensive monitoring, and have less robust efficacy data compared to JAK inhibitors and biologics 1.
What NOT to Use
Systemic Corticosteroids
The AAD makes a conditional recommendation AGAINST systemic corticosteroids for chronic AD management 1. While they may provide rapid short-term relief, they cause:
- Rebound flares upon discontinuation
- Significant long-term adverse effects (osteoporosis, diabetes, hypertension, adrenal suppression)
- Tachyphylaxis with repeated use
Use only for acute severe flares as bridge therapy while initiating other systemic agents.
Oral Antihistamines
Do not routinely prescribe oral antihistamines for AD. A 2026 systematic review and network meta-analysis found that both first- and second-generation H1 antihistamines produce only clinically unimportant reductions in AD severity (mean difference -1.87 on oSCORAD, well below the minimal important difference of 8.2) and itch severity 3.
Additionally:
- First-generation antihistamines increase cognitive impairment and treatment discontinuation
- They do not improve sleep disturbance or reduce AD exacerbations
- Second-generation agents vary in cognitive impairment risk (loratadine lowest, cetirizine/levocetirizine higher) 3
Treatment Algorithm
Confirm moderate-to-severe AD requiring systemic therapy (failed optimized topical therapy including corticosteroids, calcineurin inhibitors, or PDE4 inhibitors)
Screen for contraindications:
- Active serious infections (TB, HBV, HCV, HIV)
- History of thrombosis or cardiovascular disease
- Active malignancy
- Pregnancy/breastfeeding plans
- Severe renal/hepatic impairment
First choice: JAK inhibitor (upadacitinib, abrocitinib, or baricitinib) based on patient factors and baseline labs 1
If JAK inhibitors contraindicated: Consider dupilumab (biologic, subcutaneous) or traditional immunosuppressants in this order:
- Cyclosporine (for rapid control, ≤1 year)
- Methotrexate
- Mycophenolate
- Azathioprine
Avoid: Chronic systemic corticosteroids and routine antihistamines
Vaccinate: Ensure pneumococcal, annual influenza, and recombinant zoster vaccines are up to date before starting therapy 2
Key Differences Between Guidelines
Important nuance: The AAD dermatology guidelines and AAAAI/ACAAI allergy guidelines show some divergence on JAK inhibitor recommendations. The dermatology guidelines give strong recommendations for all three oral JAK inhibitors, while allergy guidelines show more variation in their strength of recommendations 4. This reflects different risk-benefit assessments and patient preference weighting between specialties.